- Home
- PDS vs URGN Comparison
PDS vs URGN Comparison
Compare PDS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- URGN
- Stock Information
- Founded
- PDS 1951
- URGN 2004
- Country
- PDS Canada
- URGN United States
- Employees
- PDS N/A
- URGN N/A
- Industry
- PDS
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- URGN Health Care
- Exchange
- PDS Nasdaq
- URGN Nasdaq
- Market Cap
- PDS 764.8M
- URGN 904.0M
- IPO Year
- PDS N/A
- URGN 2017
- Fundamental
- Price
- PDS $58.06
- URGN $18.87
- Analyst Decision
- PDS Buy
- URGN Strong Buy
- Analyst Count
- PDS 2
- URGN 8
- Target Price
- PDS $87.00
- URGN $28.50
- AVG Volume (30 Days)
- PDS 75.2K
- URGN 1.2M
- Earning Date
- PDS 10-28-2025
- URGN 11-05-2025
- Dividend Yield
- PDS N/A
- URGN N/A
- EPS Growth
- PDS N/A
- URGN N/A
- EPS
- PDS 5.22
- URGN N/A
- Revenue
- PDS $1,355,177,217.00
- URGN $94,238,000.00
- Revenue This Year
- PDS N/A
- URGN $39.63
- Revenue Next Year
- PDS $1.37
- URGN $111.49
- P/E Ratio
- PDS $11.12
- URGN N/A
- Revenue Growth
- PDS N/A
- URGN 10.85
- 52 Week Low
- PDS $36.20
- URGN $3.42
- 52 Week High
- PDS $67.46
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- PDS 58.61
- URGN 50.18
- Support Level
- PDS $55.85
- URGN $17.89
- Resistance Level
- PDS $59.36
- URGN $21.71
- Average True Range (ATR)
- PDS 1.51
- URGN 1.18
- MACD
- PDS -0.06
- URGN -0.25
- Stochastic Oscillator
- PDS 70.92
- URGN 25.65
About PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.